Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Statistical power can be increased
EDITOR Firstly, one might limit the inclusion of patients to those with
an intermediate prognosis Secondly, even if inclusion would be limited to patients at
intermediate risk, heterogeneity will remain regarding the probability of a favourable outcome. Predictive characteristics which account for
this heterogeneity can be adjusted for in the analysis, which will
increase the statistical power to detect a treatment
effect.4 In an analysis of patients with acute myocardial
infarction, the potential reduction in sample size was 12% by
adjustment for age.5
Besides dealing with heterogeneity, we may also consider restricting
data collection to the essential variables, such that larger numbers of
patients are accrued at the same costs. We hope that the strategies
here proposed will be applied in the study of therapy for head injury,
together with an increase in funding.
We agree with Dickinson et al1 that larger and
better designed randomised controlled trials are necessary to detect benefits of treatment in head injury.2 But increasing the
sample size is not the only solution to show efficacy. The statistical power of a study can also be improved by randomising the same number of
patients but taking prognostic factors, such as age or Glasgow coma
scale, into account.
for example, between 20% and 80% probability of a favourable outcome.3 This leads to a
focus on patients for whom treatment effects can be well determined. For the same power, a reduction in sample size of 30% might be achievable.3 After showing efficacy in the intermediate
risk group, additional funding may be raised more easily to study
patients with a poorer or better prognosis. Note that this reasoning
assumes that the relative effect of a treatment is constant across risk groups. This is in contrast to the assumption of an absolute effect of
5% as discussed by Dickinson et al. Such an absolute effect is
comparatively large at a baseline incidence of 20%, as indicated by an
odds ratio of 0.71 for the comparison of an incidence of 15% versus
20%. In contrast, the odds ratio is 0.82 for the same absolute effect
at 50% baseline incidence (45% v 50%). The absolute effect of 5% is more easily detected at a baseline incidence of 20%,
while a relative effect such as an odds ratio of 0.71 is more easily
detected at an incidence of 50%. So the assumption of an absolute or
relative effect is crucial in reasoning about power and inclusion criteria.
hukkelhoven{at}mgz.fgg.eur.nl
Ewout W Steyerberg
Andrew I R Maas
Erasmus Medical Centre Rotterdam, 3000 DR Rotterdam,
Netherlands
| 1. |
Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I.
Size and quality of randomised controlled trials in head injury: review of published studies.
BMJ
2000;
320:
1308-1311 |
| 2. | Maas AIR, Steyerberg EW, Murray GD, Bullock R, Baethmann A, Marshall LF, Teasdale GM. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations. Neurosurgery 1999; 44: 1286-1298[CrossRef][Medline]. |
| 3. | Machado SG, Murray GD, Teasdale GM. Evaluation of designs for clinical trials of neuroprotective agents in head injury. J Neurotraum 1999; 16: 1131-1138[Medline]. |
| 4. | Robinson LD, Jewell NP. Some surprising results about covariate adjustment in logistic-regression models. Int Stat Rev 1991; 59: 227-240. |
| 5. | Steyerberg EW, Bossuyt PMM, Lee KL. Clinical trials in acute myocardial infarction: Should we adjust for baseline characteristics? Am Heart J 2000; 139: 745-751[Medline]. |
More trials are needed
EDITOR To address this issue, a multicentre study to develop a set of clinical
decision rules for the management of head injured children is now in
its third month of data collection. All children with head injuries at
nine hospitals in the north west of England are seen by the attending
doctor using a tailored study pro forma. Forty clinical correlates
relating to symptoms, signs, and investigations are entered. We are
collecting patients at the rate of 1300 per month. Once 15 000 forms
have been collected, all data on admission, neurosurgical intervention,
and mortality will be collected. A set of clinical decision rules will
then be derived using recursive partitioning (as with the Ottawa ankle
guidelines). The guidelines will then be validated in a further 15 000 patients.
This is the first time that such an approach has been used in the
management of head injury, and I agree with Dickinson et al that it is
only by large, well conducted trials that we are going to advance the
evidence base in head injury
Dickinson et al are to be congratulated for highlighting the
deficiencies in research into head injury.1 The situation is no better for children with head injuries. The American Academy of
Pediatrics issued a report based on extensive literature review of 108 articles on head injury in children.2 The academy
concluded that the literature on mild head trauma does not provide a
sufficient scientific basis for evidence based recommendations about
most of the key issues in clinical management.
Wythenshawe Hospital, Manchester M23 9LT
joeldesmond{at}doctors.org.uk
1.
Dickinson K, Bunn F, Wentz R, Edwards P, Roberts I.
Size and quality of randomised controlled trials in head injury: review of published studies.
BMJ
2000;
320:
1308-1311. (13 May.)
2.
Homer CJ, Kleinman L.
Technical report: minor head injury in children.
Pediatrics
1999;
104:
e78
© BMJ 2000